A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Active:	Yes
Cancer Type:	Breast Cancer Unknown Primary	NCT ID:	NCT06188559
Trial Phases:	Phase II	Protocol IDs:	BB-1701-G000-205 (primary) NCI-2024-00539 2023-506866-30
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Eisai Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT06188559

Summary

The primary purpose of the Dose Optimization (Part 1) of this study is to assess the
safety and tolerability of BB-1701 and to determine the recommended dose (RD) of BB-1701
for Dose Expansion (Part 2). The primary purpose of Dose Expansion (Part 2) is to assess
the antitumor activity of BB-1701 at RD in the selected population(s) of breast cancer
(BC).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.